Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Pulmonary arterial hypertension is a rare and progressive disorder characterized by abnormally high blood pressure (hypertension) in the pulmonary artery. Further this is defined as a resting mean pulmonary artery pressure of 25 mm Hg or above. The condition is characterized by symptoms like shortness of breath, tiredness, chest pain, dizziness, fatigue, and swelling of the legs and ankles. Symptoms can develop slowly early and in severity among patients. Further high blood pressure in the pulmonary artery makes it difficult for the right ventricle to pump blood into the lungs. The growth of the market is due to increasing innovative products and launch. Besides increase in healthcare spending & adoption of treatment are the factors that drive the growth of the pulmonary arterial hypertension market
The key factor driving the growth of market is advancement of new technology. For instance in September 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson had announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for UPTRAVI (selexipag) as an injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults with WHO functional class (FC) II-III, who are currently prescribed oral UPTRAVI but are temporarily unable to take oral therapy. Besides growing burden of pulmonary arterial hypertension as the incidence and prevalence of PH in population-based has proven challenging, in part, because of the lack of specificity of diagnosis. Beside government and private support for the development of orphan drugs is propelling the growth of market.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the pulmonary arterial hypertension market. In addition, complete analysis of changes on the pulmonary arterial hypertension market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. COVID-19 impact was moderate on the pulmonary arterial hypertension market as the pandemic had led to stop the major production and supply for months
The pulmonary arterial hypertension market is segmented based on by drug class, type, diagnosis, treatment, end users, sales channel and geography.
The pulmonary arterial hypertension has different drug class like endothelin receptor antagonists (eras), prostacyclin and prostacyclin analogs, sgc stimulators, pde-5 dipsticks. Endothelin receptor antagonists (eras) followed by prostacyclin and prostacyclin analogs accounted the significant market share in the pulmonary arterial hypertension market. The growth of endothelin receptor antagonists is due to advanced management of hypertension, as endothelin is one of the most potent vasoconstrictors and has significant increase in the sales of this drug. Besides prostacyclin and prostacyclin analogs have shown to improve symptoms and short-term survival in human patients with pulmonary hypertension thereby fueling the market demand and growth.
The pulmonary arterial hypertension is available according to different type including idiopathic, heritable, associated. Idiopathic pulmonary arterial hypertension is major type of disease observed in pulmonary arterial hypertension market. It is high blood pressure in the arteries (blood vessels) of the lungs. The right side of the heart work harder to push blood to the lungs. The growth of segment is ultimately fueling the demand for pulmonary arterial hypertension market.
The pulmonary arterial hypertension is diagnose by blood tests, chest x-ray, electrocardiogram (ecg), echocardiogram, right heart catheterization, polysomnogra. The blood test is mostly performed owing the easy available and detection. Besides electrocardiogram (ecg) provide supportive evidence to investigate symptoms of a possible heart problem, such as chest pain, palpitations (suddenly noticeable heartbeats), dizziness and shortness of breath. These signals are further recorded by a machine and are looked at by a doctor to diagnose the condition.
The pulmonary arterial hypertension has various treatment including medication, surgery, therapy. Therapy is widely prefer for pulmonary arterial hypertension as preventing the disease from worsening. Further these are based on patient-specific factors and response. However, in worse cases surgery play a major important role in patients where medical therapy is unavailable or has been unsuccessful.
The pulmonary arterial hypertension has end use in hospitals, specialty clinics, and home healthcare. Hospital is the major end user owing to advanced services like diagnosis tool and facilities provided for patient’s treatment. Also, rising inflow of patient in hospital is further fueling the demand for pulmonary arterial hypertension market. Moreover, hospital plays major in analysis, diagnosis and treatment of patients.
The pulmonary arterial hypertension is distributed through following sales channel like hospital pharmacy, retail pharmacy, and online pharmacy. Hospital pharmacy leads in the pulmonary arterial hypertension owing to professionalize the functioning of the pharmaceutical services in hospitals thereby ensuring availability of the required medication at an affordable cost at the required time. Also, hospital pharmacy help the patients , medical staff, nurses and others involved in patient care on the use of drugs, possible side effects, toxicity, adverse effects, drug interactions etc. The hospital pharmacy has huge demand owing to presence in the hospital area. Whereas, online pharmacy provides accessibility to people in remote areas as well as urban areas further providing discounts, doorstep delivery within a short time, and validation of prescription.
Geographically the global pulmonary arterial hypertension market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW). North America is expected to dominate in the global pulmonary arterial hypertension market due to rise in healthcare expenditure and core manufacturing are contributing to the growth of the market in the region. Besides the growing awareness regarding pulmonary arterial hypertension and increasing diagnosis for the disease is fueling the growth of the market in the region. Also, developed facilitates access to advanced therapeutics for treating pulmonary arterial hypertension is boosting the growth of region. On the other hand Asia Pacific is anticipated to witness the highest growth owing to increasing population, emerging economy and improving healthcare facilities & system is driving the growth of the region. Furthermore Europe is projected to register significant growth during forecast period attributing to rising cases of pulmonary arterial hypertension (PHA) in the region
The key players in pulmonary arterial hypertension market are Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co. Inc., Novartis International AG, Pfizer, Inc. and United Therapeutics Corporation among others.
August 2020: United Therapeutics Corporation had announced the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency's review to be complete in April 2021.
The report analyses the pulmonary arterial hypertension market based on by drug class, type, diagnosis, treatment, end users, sales channel and geography. The pulmonary arterial hypertension has different drug class like endothelin receptor antagonists (eras), prostacyclin and prostacyclin analogs, sgc stimulators, pde-5 dipsticks. The pulmonary arterial hypertension is available according to different type including idiopathic, heritable, associated. The pulmonary arterial hypertension is diagnose by blood tests, chest x-ray, electrocardiogram (ecg), echocardiogram, right heart catheterization, polysomnogra. The pulmonary arterial hypertension has various treatment including medication, surgery, therapy. The market has end use in hospitals, specialty clinics, and home healthcare. The pulmonary arterial hypertension is distributed through following sales channel like hospital pharmacy, retail pharmacy, and online pharmacy. Geographically the global pulmonary arterial hypertension market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW).
The key players in pulmonary arterial hypertension market are Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co. Inc., Novartis International AG, Pfizer, Inc. and United Therapeutics Corporation among others.
Why to buy this report:
